HCW Biologics Inc
HCWB4.130USD
+0.005+0.12%
Market hours （ET）Quotes delayed by 15 min
4.64MMarket Cap
LossP/E TTM
More Details of HCW Biologics Inc Company
HCW Biologics Inc. is a clinical-stage biopharmaceutical company. It is focused on discovering and developing novel immunotherapies to lengthen health span by disrupting the link between chronic, low-grade inflammation, and age-related diseases, such as cancer, cardiovascular diseases, diabetes, neurodegenerative diseases, autoimmune diseases, as well as other conditions such as long-haul COVID-19. It has developed a Tissue factOr-Based fusion (TOBI) discovery platform to generate designer, novel multi-functional fusion molecules with immunotherapeutic properties. Its lead product candidates include HCW9218 and HCW9302. HCW9218 is a bifunctional immunotherapeutic designed with the capabilities to neutralize transforming growth factor-β and stimulate immune cells, targeting senescent cells and the SASP factors they secrete. HCW9302 is designed to activate and expand regulatory T cells, which deactivate inflammasomes. Its other product candidates include HCW9201, HCW9206, and others.
Company Info
Ticker SymbolHCWB
Company nameHCW Biologics Inc
IPO dateJul 20, 2021
CEODr. Hing C. Wong, Ph.D.
Number of employees36
Security typeOrdinary Share
Fiscal year-endJul 20
Address2929 N Commerce Pkwy
CityMIRAMAR
Stock exchangeNASDAQ Capital Market Consolidated
CountryUnited States of America
Postal code33025
Phone19548422024
Websitehttps://hcwbiologics.com/
Ticker SymbolHCWB
IPO dateJul 20, 2021
CEODr. Hing C. Wong, Ph.D.
Company Executives
Name
Name/Position
Position
Shareholding
Change
Dr. Hing C. Wong, Ph.D.
Dr. Hing C. Wong, Ph.D.
Chief Executive Officer, Founder, Director
Chief Executive Officer, Founder, Director
509.96K
+27.06%
Ms. Rebecca Byam
Ms. Rebecca Byam
Chief Financial Officer
Chief Financial Officer
43.01K
+24.49%
Mr. Scott T. Garrett
Mr. Scott T. Garrett
Independent Chairman of the Board
Independent Chairman of the Board
25.50K
+280.84%
Mr. Lee Flowers
Mr. Lee Flowers
Senior Vice President - Business Development
Senior Vice President - Business Development
5.72K
+20.23%
Dr. Peter Rhode, Ph.D.
Dr. Peter Rhode, Ph.D.
Chief Scientific Officer, Vice President - Clinical Operations
Chief Scientific Officer, Vice President - Clinical Operations
1.94K
--
Ms. Lisa M. Giles
Ms. Lisa M. Giles
Independent Director
Independent Director
896.00
--
Mr. Rick S. Greene
Mr. Rick S. Greene
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Dr. Hing C. Wong, Ph.D.
Dr. Hing C. Wong, Ph.D.
Chief Executive Officer, Founder, Director
Chief Executive Officer, Founder, Director
509.96K
+27.06%
Ms. Rebecca Byam
Ms. Rebecca Byam
Chief Financial Officer
Chief Financial Officer
43.01K
+24.49%
Mr. Scott T. Garrett
Mr. Scott T. Garrett
Independent Chairman of the Board
Independent Chairman of the Board
25.50K
+280.84%
Mr. Lee Flowers
Mr. Lee Flowers
Senior Vice President - Business Development
Senior Vice President - Business Development
5.72K
+20.23%
Dr. Peter Rhode, Ph.D.
Dr. Peter Rhode, Ph.D.
Chief Scientific Officer, Vice President - Clinical Operations
Chief Scientific Officer, Vice President - Clinical Operations
1.94K
--
Ms. Lisa M. Giles
Ms. Lisa M. Giles
Independent Director
Independent Director
896.00
--
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Fri, Aug 1
Updated: Fri, Aug 1
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Wong (Hing C)
25.87%
Byam (Rebecca)
2.18%
Garrett (Scott T)
1.29%
Avantax Planning Partners, Inc
0.35%
The Vanguard Group, Inc.
0.31%
Other
69.99%
Shareholders
Shareholders
Proportion
Wong (Hing C)
25.87%
Byam (Rebecca)
2.18%
Garrett (Scott T)
1.29%
Avantax Planning Partners, Inc
0.35%
The Vanguard Group, Inc.
0.31%
Other
69.99%
Shareholder Types
Shareholders
Proportion
Individual Investor
30.09%
Investment Advisor
0.92%
Investment Advisor/Hedge Fund
0.51%
Research Firm
0.02%
Other
68.46%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
40
619.84K
31.44%
+87.21K
2025Q1
40
480.61K
42.86%
-46.33K
2024Q4
37
23.10M
51.86%
+2.14M
2024Q3
33
21.13M
54.31%
+156.07K
2024Q2
33
21.19M
54.45%
+322.27K
2024Q1
34
20.93M
57.88%
+1.69M
2023Q4
33
19.30M
53.71%
+122.06K
2023Q3
33
19.17M
53.35%
-2.58K
2023Q2
33
22.70M
63.26%
-3.42M
2023Q1
32
22.37M
62.46%
-3.36M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Wong (Hing C)
509.96K
25.87%
+108.61K
+27.06%
May 16, 2025
Byam (Rebecca)
43.01K
2.18%
+8.46K
+24.49%
May 12, 2025
Garrett (Scott T)
25.50K
1.29%
+18.81K
+280.84%
May 16, 2025
Avantax Planning Partners, Inc
6.99K
0.35%
--
--
Mar 31, 2025
The Vanguard Group, Inc.
6.08K
0.31%
+5.14K
+545.33%
Mar 31, 2025
Geode Capital Management, L.L.C.
5.92K
0.3%
+1.38K
+30.23%
Mar 31, 2025
Flowers (Lee)
5.72K
0.29%
+962.00
+20.23%
May 08, 2025
Winer (Gary M)
4.08K
0.21%
+3.65K
+858.82%
May 16, 2025
Cresset Asset Management, LLC
3.30K
0.17%
--
--
Mar 31, 2025
Greene (Rick Scott)
2.07K
0.1%
+962.00
+87.14%
May 12, 2025
View more
Related ETFs
Updated: Sat, Aug 2
Updated: Sat, Aug 2
Name
Proportion
iShares Micro-Cap ETF
0%
iShares Micro-Cap ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
